ARS Pharma Files 10-Q, Details Key Agreements
Ticker: SPRY · Form: 10-Q · Filed: May 14, 2025 · CIK: 1671858
| Field | Detail |
|---|---|
| Company | Ars Pharmaceuticals, Inc. (SPRY) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, agreements
TL;DR
ARS Pharma 10-Q filed. Shows financial status and ongoing deals with Alfresa, Seqirus, Recordati.
AI Summary
ARS Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities. Key agreements mentioned include those with Alfresa, Seqirus, and Recordati, with specific dates ranging from March 2020 to August 2024.
Why It Matters
This filing provides insight into ARS Pharmaceuticals' financial health and ongoing business relationships, which can impact its stock performance and future development.
Risk Assessment
Risk Level: medium — The filing contains information about financial performance and business operations, which inherently carry risks for investors.
Key Numbers
- 20250331 — Reporting Period End Date (Quarterly Report)
- 20250514 — Filing Date (SEC Filing)
Key Players & Entities
- ARS Pharmaceuticals, Inc. (company) — Filer
- Silverback Therapeutics, Inc. (company) — Former Company Name
- Alfresa (company) — License Agreement Partner
- Seqirus (company) — License Agreement Partner
- Recordati (company) — License Agreement Partner
- Aegis Therapeutics LLC (company) — Mentioned Entity
FAQ
What is the primary purpose of the 10-Q filing for ARS Pharmaceuticals, Inc. for the period ending March 31, 2025?
The 10-Q filing provides a comprehensive overview of ARS Pharmaceuticals, Inc.'s financial performance and business activities for the first quarter of 2025.
What are some of the key agreements mentioned in the filing and their associated dates?
The filing mentions license agreements with Alfresa (March 2020 - March 2020), Seqirus (August 2024 - August 2024), and Recordati (January 2020 - December 2020).
What was ARS Pharmaceuticals, Inc.'s former company name?
ARS Pharmaceuticals, Inc.'s former company name was Silverback Therapeutics, Inc., with a date of name change on April 12, 2016.
What is the business address and phone number for ARS Pharmaceuticals, Inc.?
The business address is 11682 El Camino Real, Suite 120, San Diego, CA 92130, and the business phone number is 858-771-9307.
What SIC code is ARS Pharmaceuticals, Inc. classified under?
ARS Pharmaceuticals, Inc. is classified under SIC code 2834, which pertains to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding ARS Pharmaceuticals, Inc. (SPRY).